Navigation Links
Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
Date:6/2/2008

81308 for Phase 2 studies where LY2181308 will be evaluated in combination with other oncology agents.

"The progress our partners are making with our antisense drugs demonstrate the potential of antisense technology to provide new, first-in-class treatment options to treat a variety of cancers. Antisense drugs are highly selective for their targets which minimizes the off target interactions that are responsible for so many toxicities observed with traditional drugs in oncology studies," said Brett Monia, Ph.D., Vice President of Drug Discovery Research at Isis Pharmaceuticals. "The encouraging safety profiles observed in both Lilly's and OncoGenex's studies support further clinical evaluation of both drugs."

OGX-011 and LY2181308 are part of Isis' cancer portfolio of first-in-class drugs, which act upon biological targets associated with cancer progression and/or treatment resistance. The distribution of antisense drugs to tumor cells and the high degree of specificity of these drugs to their target make them attractive new treatment options for a broad range of cancers.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or ex
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
2. Briefing on a new Web resource to address global drinking water crisis
3. St. Petersburg: Candlelight Vigil to Raise Awareness of Florida HIV/AIDS Crisis, Honor Lives Lost
4. Isis Acquires Symphony GenIsis
5. New Denver Area Program Developed For Teens in Crisis
6. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
7. March of Dimes NICU Family Support(R) Programs Give Wisconsin Families Comfort and Information during a Crisis
8. March of Dimes NICU Family Support(R) Programs Give Florida Families Comfort and Information During a Crisis
9. Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
10. Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
11. Survey of Iowa Voters Reveals Surprising Results and Attitudes Toward Americas Health Care Crisis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected ... Stewart American Made Awards (MSAMAs), an annual competition in ... the fields of crafts, design, food and style. ... in the MSAMAs, which celebrates entrepreneurs and artisans who ... communities and changing the way we shop, work and ...
(Date:10/1/2014)... 2014 Nordic Naturals is kicking ... special cause. The campaign—“Buy One Bottle. Help Two ... Veterans, a nonprofit organization that helps rebuild the ... dogs that would otherwise face euthanasia. From October ... support monthly donations of Nordic Naturals omega-3s to ...
Breaking Medicine News(10 mins):Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... , , , SEATTLE, July 17 ... by exacerbating conditions like hypertension, stress and fatigue, but also by causing people ... , Physicians at The Polyclinic in Seattle are offering suggestions for ... health. , , Don, t put ...
... , WASHINGTON, July 17 The Association ... Director of Policy and Public Affairs, in response to the AMA,s endorsement ... American Medical Association has sold out patients and the profession by endorsing ... "Why did the AMA do it? For a few dollars increase ...
... , , , ... (Nasdaq: NGSX ) announced today that Bruce A. Peacock has ... on his responsibilities as CEO of privately-held Alba Therapeutics. , ... no opportune time to resign, I feel confident that NeurogesX is well ...
... and avoided vitamin B deficiency , FRIDAY, July ... gastric bypass surgery helps patients lose weight faster and ... Probiotics are the "good" bacteria found in yogurt and ... University School of Medicine study included 44 patients who ...
... , CAMBRIDGE, Mass., July 17 Biopure Corporation ... The Nasdaq Stock Market, by letter dated July 17, 2009, that its ... because of concerns raised by the Company,s filing for protection under Chapter ... of business on July 28, 2009. , , ...
... , Cabinet Secretaries Kathleen Sebelius, Hilda L. ... community forum and hold m edi ... WASHINGTON , July 17 U.S. Department of ... U.S. Department of Agriculture Secretary Tom Vilsack and U.S. Department of Veterans Affairs Secretary Eric ...
Cached Medicine News:Health News:How to Afford Health Care in Hard Times 2Health News:Doctors: AMA Has Sold Out Patients & the Profession For A Few Dollars 2Health News:NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors 2Health News:NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors 3Health News:NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors 4Health News:Top Obama administration officials to hold rural health community forum 2
(Date:9/30/2014)... 2014 This study provides an analysis ... solutions including nuclear imaging informatics, PET imaging informatics, ... assesses the size of the market based on ... projects future growth based on the current drivers ... place in the broader markets for imaging equipment, ...
(Date:9/30/2014)... -- Decision Resources Group finds that the Asia Pacific ... China , India , Japan ... 2023. Dental implant procedure volumes will grow as physicians are increasingly ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Puma Biotechnology, Inc., a development stage biopharmaceutical ... license the worldwide commercial rights to neratinib, a ... transduction through the epidermal growth factor receptors, ErbB1 ... is being studied in the neoadjuvant, adjuvant and ...
... Corp. (OTCQB: CYCA), leading the way to cost effective ... Erik Stephansen to President of its eHealth division.  Mr. ... part of the company,s recent launch of their CyttaConnect™ ... network and its partners, FDA approved Bluetooth medical devices. ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5New Leader for CyttaConnect™ Medical Monitoring eHealth Division 2New Leader for CyttaConnect™ Medical Monitoring eHealth Division 3